Short Interest in Assembly Biosciences, Inc. (NASDAQ:ASMB) Grows By 207.1%

Assembly Biosciences, Inc. (NASDAQ:ASMBGet Free Report) was the recipient of a significant growth in short interest in March. As of March 15th, there was short interest totalling 60,200 shares, a growth of 207.1% from the February 29th total of 19,600 shares. Approximately 1.6% of the shares of the company are short sold. Based on an average daily volume of 29,900 shares, the short-interest ratio is currently 2.0 days.

Insider Transactions at Assembly Biosciences

In other Assembly Biosciences news, major shareholder Alexander Schornstein bought 24,999 shares of Assembly Biosciences stock in a transaction dated Wednesday, January 17th. The stock was purchased at an average price of $9.36 per share, for a total transaction of $233,990.64. Following the completion of the purchase, the insider now directly owns 655,357 shares of the company’s stock, valued at $6,134,141.52. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On Assembly Biosciences

Several hedge funds have recently bought and sold shares of ASMB. Jane Street Group LLC bought a new stake in Assembly Biosciences during the first quarter valued at approximately $27,000. Tower Research Capital LLC TRC lifted its position in Assembly Biosciences by 110.2% during the third quarter. Tower Research Capital LLC TRC now owns 17,150 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 8,992 shares during the last quarter. JPMorgan Chase & Co. lifted its position in Assembly Biosciences by 15,633.0% during the first quarter. JPMorgan Chase & Co. now owns 14,789 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 14,695 shares during the last quarter. UBS Group AG lifted its position in Assembly Biosciences by 110.0% during the fourth quarter. UBS Group AG now owns 24,007 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 12,576 shares during the last quarter. Finally, Two Sigma Investments LP bought a new stake in shares of Assembly Biosciences in the 1st quarter worth approximately $32,000. 19.92% of the stock is currently owned by institutional investors.

Assembly Biosciences Stock Performance

ASMB stock opened at $13.38 on Thursday. The firm has a 50 day moving average of $12.03 and a 200-day moving average of $10.56. Assembly Biosciences has a 12 month low of $7.69 and a 12 month high of $20.04.

About Assembly Biosciences

(Get Free Report)

Assembly Biosciences, Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study.

See Also

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.